It is of interest that ALKBH2 is frequently upregulated in glioblastomas, and patients with high expression levels have a reduced overall survival [45], supporting this view and suggesting ALKBH2 as a potential prognostic biomarker in gliomas. Here, ALKBH2 is linked to central nervous system cancer.